IL282854B - Treatment and inhibition of fibrosis in non-alcoholic fatty liver disease patients - Google Patents

Treatment and inhibition of fibrosis in non-alcoholic fatty liver disease patients

Info

Publication number
IL282854B
IL282854B IL282854A IL28285421A IL282854B IL 282854 B IL282854 B IL 282854B IL 282854 A IL282854 A IL 282854A IL 28285421 A IL28285421 A IL 28285421A IL 282854 B IL282854 B IL 282854B
Authority
IL
Israel
Prior art keywords
fibrosis
inhibition
treatment
liver disease
fatty liver
Prior art date
Application number
IL282854A
Other languages
Hebrew (he)
Other versions
IL282854A (en
Inventor
Hayardeny-Nisimov Liat
Tali Gorfine
Baharaff Allen
De La Paz Jose M Mato
Original Assignee
Galmed Res And Development Ltd
Liat Hayardeny Nisimov
Tali Gorfine
Baharaff Allen
De La Paz Jose M Mato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/182,767 external-priority patent/US20190175619A1/en
Application filed by Galmed Res And Development Ltd, Liat Hayardeny Nisimov, Tali Gorfine, Baharaff Allen, De La Paz Jose M Mato filed Critical Galmed Res And Development Ltd
Publication of IL282854A publication Critical patent/IL282854A/en
Publication of IL282854B publication Critical patent/IL282854B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL282854A 2018-11-07 2021-05-02 Treatment and inhibition of fibrosis in non-alcoholic fatty liver disease patients IL282854B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/182,767 US20190175619A1 (en) 2016-11-10 2018-11-07 Treatment of fibrosis, and inhibition of fibrosis in non-alcoholic fatty liver disease patients
PCT/IL2019/051121 WO2020095293A1 (en) 2018-11-07 2019-10-16 Treatment and inhibition of fibrosis in non-alcoholic fatty liver disease patients

Publications (2)

Publication Number Publication Date
IL282854A IL282854A (en) 2021-06-30
IL282854B true IL282854B (en) 2021-12-01

Family

ID=70611747

Family Applications (1)

Application Number Title Priority Date Filing Date
IL282854A IL282854B (en) 2018-11-07 2021-05-02 Treatment and inhibition of fibrosis in non-alcoholic fatty liver disease patients

Country Status (8)

Country Link
EP (1) EP3876945A4 (en)
CN (1) CN113301902A (en)
AU (1) AU2019376907A1 (en)
BR (1) BR112021008896A2 (en)
CA (1) CA3117958A1 (en)
IL (1) IL282854B (en)
MX (1) MX2021005420A (en)
WO (1) WO2020095293A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197870B2 (en) * 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
US20190175619A1 (en) * 2016-11-10 2019-06-13 Galmed Research And Development Ltd. Treatment of fibrosis, and inhibition of fibrosis in non-alcoholic fatty liver disease patients
MX2019005533A (en) * 2016-11-10 2020-02-07 Galmed Res And Development Ltd Treatment for fibrosis.

Also Published As

Publication number Publication date
MX2021005420A (en) 2021-09-10
BR112021008896A2 (en) 2021-08-10
EP3876945A4 (en) 2022-08-24
CN113301902A (en) 2021-08-24
CA3117958A1 (en) 2020-05-14
EP3876945A1 (en) 2021-09-15
WO2020095293A1 (en) 2020-05-14
AU2019376907A1 (en) 2021-06-24
IL282854A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
IL279161A (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
IL273550A (en) Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation
IL275188A (en) Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis
EP3829575A4 (en) Rbp4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout
IL272869A (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
IL272465A (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
IL268502A (en) Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
IL289167A (en) 2h-indazole derivatives and their use in the treatment of disease
IL274578A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
IL280315A (en) Methods of treatment and prevention of alzheimer's disease
ZA202007834B (en) Compositions comprising amino acids for use in the prevention and treatment of liver diseases
EP3781158A4 (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
IL282251A (en) Compositions and methods for treatment of liver disease
EP3880223A4 (en) Apple peel polyphenol extract for the prevention and the treatment of non-alcoholic fatty liver disease
HK1257589A1 (en) Medicine for preventing and treating tissue and organ fibrosis and use of the medicine
IL275925A (en) Prevention and treatment of organ fibrosis
EP3913002A4 (en) Application of ecm1 in prevention and/or treatment of liver fibrosis-related diseases
EP3549596A4 (en) Use of microcystins in preparation of drugs for preventing or treating organ and tissue fibrosis diseases
IL272495A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
IL282854A (en) Treatment and inhibition of fibrosis in non-alcoholic fatty liver disease patients
ZA201906964B (en) Prevention and/or treatment of inflammatory skin disease
IL285776A (en) Compositions useful in treatment of krabbe disease
PT3595660T (en) Compounds for use in the prevention and/or treatment of non-alcoholic fat liver disease and non-alcoholic steatohepatitis
EP4069209A4 (en) Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
EP4069208A4 (en) Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease